{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:01:01Z","timestamp":1792094461803,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health and Medical Education and the National Institute for Health Research, Tehran University of Medical Sciences, Iran","award":["grant No.241\/M\/9839"],"award-info":[{"award-number":["grant No.241\/M\/9839"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The study aimed to estimate the prevalence of lipid abnormalities in Iranian adults by demographic characterization, geographical distribution, and associated risk factors using national and sub-national representative samples of the STEPs 2021 survey in Iran. In this population-based household survey, a total of 18,119 individuals aged over 25 years provided blood samples for biochemical analysis. Dyslipidemia was defined by the presence of at least one of the lipid abnormalities of hypertriglyceridemia (\u2265\u2009150\u00a0mg\/dL), hypercholesterolemia (\u2265\u2009200\u00a0mg\/dL), high LDL-C (\u2265\u2009130\u00a0mg\/dL), and low HDL-C (&lt;\u200950\u00a0mg\/dL in women,\u2009&lt;\u200940\u00a0mg\/dL in men), or self-reported use of lipid-lowering medications. Mixed dyslipidemia was characterized as the coexistence of high LDL-C with at least one of the hypertriglyceridemia and low HDL-C. The prevalence of each lipid abnormality was determined by each population strata, and the determinants of abnormal lipid levels were identified using a multiple logistic regression model. The prevalence was 39.7% for hypertriglyceridemia, 21.2% for hypercholesterolemia, 16.4% for high LDL-C, 68.4% for low HDL-C, and 81.0% for dyslipidemia. Hypercholesterolemia and low HDL-C were more prevalent in women, and hypertriglyceridemia was more prevalent in men. The prevalence of dyslipidemia was higher in women (OR\u2009=\u20091.8), obese (OR\u2009=\u20092.8) and overweight (OR\u2009=\u20092.3) persons, those residents in urban areas (OR\u2009=\u20091.1), those with inappropriate physical activity (OR\u2009=\u20091.2), patients with diabetes (OR\u2009=\u20092.7) and hypertension (OR\u2009=\u20091.9), and participants with a history (OR\u2009=\u20091.6) or familial history of CVDs (OR\u2009=\u20091.2). Mixed dyslipidemia prevalence was 13.6% in women and 11.4% in men (P\u2009&lt;\u20090.05). The prevalence of lipid abnormalities was highly heterogeneous among provinces, and East Azarbaijan with 85.3% (81.5\u201389.1) and Golestan with 68.5% (64.8\u201372.2) had the highest and lowest prevalence of dyslipidemia, respectively. Although the prevalence of high cholesterol and LDL-C had a descending trend in the 2016\u20132021 period, the prevalence of dyslipidemia remained unchanged. There are modifiable risk factors associated with dyslipidemia that can be targeted by the primary healthcare system. To modify these risk factors and promote metabolic health in the country, action plans should come to action through a multi-sectoral and collaborative approach.<\/jats:p>","DOI":"10.1038\/s41598-023-42341-5","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T07:02:38Z","timestamp":1695106958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prevalence of plasma lipid abnormalities and associated risk factors among Iranian adults based on the findings from STEPs survey 2021"],"prefix":"10.1038","volume":"13","author":[{"given":"Javad","family":"Khanali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Mahdi","family":"Rashidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed-Hadi","family":"Ghamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Azangou-Khyavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Malekpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Abbasi-Kangevari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Melika","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Naderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezou","family":"Dilmaghani-Marand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Farzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moein","family":"Yoosefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirali","family":"Hajebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahabeddin","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Azadnajafabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Fattahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Nasserinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Abdolhamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Haghshenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazila","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Djalalinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagher","family":"Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Farzadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"42341_CR1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth, G. A. et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: Update From the GBD 2019 Study. J. Am. Coll. Cardiol. 76, 2982\u20133021 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"42341_CR2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","unstructured":"GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 396, 1223\u20131249 (2020).","journal-title":"Lancet"},{"key":"42341_CR3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(19)30179-2","volume":"7","author":"F Azizi","year":"2019","unstructured":"Azizi, F. et al. Metabolic health in the Middle East and north Africa. Lancet Diabetes Endocrinol. 7, 866\u2013879 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"42341_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-020-00709-8","author":"S Azadnajafabad","year":"2021","unstructured":"Azadnajafabad, S. et al. Non-communicable diseases\u2019 risk factors in Iran; a review of the present status and action plans. J. Diabetes Metab. Disord. https:\/\/doi.org\/10.1007\/s40200-020-00709-8 (2021).","journal-title":"J. Diabetes Metab. Disord."},{"key":"42341_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.4103\/ijpvm.IJPVM_379_19","volume":"11","author":"A VataniNezafat","year":"2020","unstructured":"VataniNezafat, A., Tavakolifard, N. & Vaezi, A. Adherence of general practitioners to the national hypertension guideline, Isfahan, Iran. Int. J. Prev. Med. 11, 130 (2020).","journal-title":"Int. J. Prev. Med."},{"key":"42341_CR6","first-page":"449","volume":"43","author":"MP AkbartabarToori","year":"2018","unstructured":"AkbartabarToori, M. P. et al. Prevalence of hypercholesterolemia, high LDL, and low HDL in Iran: A systematic review and meta-analysis. Iran. J. Med. Sci. 43, 449\u2013465 (2018).","journal-title":"Iran. J. Med. Sci."},{"key":"42341_CR7","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/S0140-6736(17)32252-3","volume":"390","author":"M Dehghan","year":"2017","unstructured":"Dehghan, M. et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): A prospective cohort study. Lancet 390, 2050\u20132062 (2017).","journal-title":"Lancet"},{"key":"42341_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5534\/wjmh.2015.33.3.167","volume":"33","author":"A Mohammadbeigi","year":"2015","unstructured":"Mohammadbeigi, A., Moshiri, E., Mohammadsalehi, N., Ansari, H. & Ahmadi, A. Dyslipidemia prevalence in Iranian adult men: The impact of population-based screening on the detection of undiagnosed patients. World J. Mens. Health 33, 167\u2013173 (2015).","journal-title":"World J. Mens. Health"},{"key":"42341_CR9","first-page":"109","volume":"20","author":"S Farsaei","year":"2015","unstructured":"Farsaei, S., Sabzghabaee, A. M., Amini, M. & Zargarzadeh, A. H. Adherence to statin therapy in patients with type 2 diabetes: An important dilemma. J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci. 20, 109\u2013114 (2015).","journal-title":"J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci."},{"key":"42341_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.jacl.2018.08.001","volume":"12","author":"Z Aryan","year":"2018","unstructured":"Aryan, Z. et al. The prevalence, awareness, and treatment of lipid abnormalities in Iranian adults: Surveillance of risk factors of noncommunicable diseases in Iran 2016. J. Clin. Lipidol. 12, 1471-1481.e4 (2018).","journal-title":"J. Clin. Lipidol."},{"key":"42341_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2105\/AJPH.2015.302962","volume":"106","author":"L Riley","year":"2016","unstructured":"Riley, L. et al. The World Health Organization STEPwise approach to noncommunicable disease risk-factor surveillance: Methods, challenges, and opportunities. Am. J. Public Health 106, 74\u201378 (2016).","journal-title":"Am. J. Public Health"},{"key":"42341_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.34172\/aim.2022.99","volume":"25","author":"S Djalalinia","year":"2022","unstructured":"Djalalinia, S. et al. Protocol design for surveillance of risk factors of non-communicable diseases during the COVID-19 pandemic: An experience from Iran STEPS survey 2021. Arch Iran Med. 25, 634\u2013646 (2022).","journal-title":"Arch Iran Med."},{"key":"42341_CR13","unstructured":"Cluster, W. H. O. N. D. and M. H. WHO STEPS surveillance manual: the WHO STEPwise approach to chronic disease risk factor surveillance\/Noncommunicable Diseases and Mental Health, World Health Organization."},{"key":"42341_CR14","doi-asserted-by":"publisher","first-page":"10272","DOI":"10.1038\/s41598-023-37299-3","volume":"13","author":"M Abbasi-Kangevari","year":"2023","unstructured":"Abbasi-Kangevari, M. et al. Tobacco consumption patterns among Iranian adults: A national and sub-national update from the STEPS survey 2021. Sci. Rep. 13, 10272 (2023).","journal-title":"Sci. Rep."},{"key":"42341_CR15","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1007\/s00394-019-02153-8","volume":"59","author":"A Gholami","year":"2020","unstructured":"Gholami, A. et al. Is salt intake reduction a universal intervention for both normotensive and hypertensive people: A case from Iran STEPS survey 2016. Eur. J. Nutr. 59, 3149\u20133161 (2020).","journal-title":"Eur. J. Nutr."},{"key":"42341_CR16","unstructured":"ADA. Diagnosis | ADA. The Path to Understanding Diabetes Starts Here (2011)."},{"key":"42341_CR17","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection, Evaluation, and T. of H. B. C. in A","year":"2001","unstructured":"Expert Panel on Detection, Evaluation, and T. of H. B. C. in A. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285, 2486\u20132497 (2001).","journal-title":"JAMA"},{"key":"42341_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12944-020-01204-y","volume":"19","author":"M Hedayatnia","year":"2020","unstructured":"Hedayatnia, M. et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis. 19, 42 (2020).","journal-title":"Lipids Health Dis."},{"key":"42341_CR19","doi-asserted-by":"publisher","first-page":"e96808","DOI":"10.1371\/journal.pone.0096808","volume":"9","author":"SR Joshi","year":"2014","unstructured":"Joshi, S. R. et al. Prevalence of dyslipidemia in urban and rural India: The ICMR-INDIAB study. PLoS ONE 9, e96808 (2014).","journal-title":"PLoS ONE"},{"key":"42341_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jacl.2013.12.011","volume":"8","author":"F Bayram","year":"2014","unstructured":"Bayram, F. et al. Prevalence of dyslipidemia and associated risk factors in Turkish adults. J. Clin. Lipidol. 8, 206\u2013216 (2014).","journal-title":"J. Clin. Lipidol."},{"key":"42341_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jacl.2009.12.004","volume":"4","author":"YS Khader","year":"2010","unstructured":"Khader, Y. S., Batieha, A., El-Khateeb, M., Al Omari, M. & Ajlouni, K. Prevalence of dyslipidemia and its associated factors among Jordanian adults. J. Clin. Lipidol. 4, 53\u201358 (2010).","journal-title":"J. Clin. Lipidol."},{"key":"42341_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12944-017-0453-2","volume":"16","author":"F-L Zhang","year":"2017","unstructured":"Zhang, F.-L. et al. The prevalence, awareness, treatment, and control of dyslipidemia in northeast China: A population-based cross-sectional survey. Lipids Health Dis. 16, 61 (2017).","journal-title":"Lipids Health Dis."},{"key":"42341_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1036219","author":"SA Nejadghaderi","year":"2021","unstructured":"Nejadghaderi, S. A. et al. Physical activity pattern in Iran: Findings from STEPS 2021. Front. Public Health https:\/\/doi.org\/10.3389\/fpubh.2022.1036219 (2021).","journal-title":"Front. Public Health"},{"key":"42341_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043894","author":"S Djalalinia","year":"2021","unstructured":"Djalalinia, S. et al. The levels of BMI and patterns of obesity and overweight during the COVID-19 pandemic: Experience from the Iran STEPs 2021 survey. Front. Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2022.1043894 (2021).","journal-title":"Front. Endocrinol."},{"key":"42341_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.arteri.2013.12.001","volume":"26","author":"S Martinez-Hervas","year":"2014","unstructured":"Martinez-Hervas, S. et al. Prevalence of plasma lipid abnormalities and its association with glucose metabolism in Spain: The di@bet.es study. Clin. e Investig. en Arterioscler. Publ. Of. la Soc. Esp. Arterioscler. 26, 107\u2013114 (2014).","journal-title":"Clin. e Investig. en Arterioscler. Publ. Of. la Soc. Esp. Arterioscler."},{"key":"42341_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40200-017-0288-4","volume":"16","author":"N Peykari","year":"2017","unstructured":"Peykari, N. et al. National action plan for non-communicable diseases prevention and control in Iran; a response to emerging epidemic. J. Diabetes Metab. Disord. 16, 3 (2017).","journal-title":"J. Diabetes Metab. Disord."},{"key":"42341_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40200-016-0268-0","volume":"15","author":"H Najafipour","year":"2016","unstructured":"Najafipour, H. et al. Prevalence of dyslipidemia and its association with other coronary artery disease risk factors among urban population in Southeast of Iran: Results of the Kerman coronary artery disease risk factors study (KERCADRS). J. Diabetes Metab. Disord. 15, 49 (2016).","journal-title":"J. Diabetes Metab. Disord."},{"key":"42341_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ehj.2013.05.003","volume":"65","author":"A El Etriby","year":"2013","unstructured":"El Etriby, A., Bramlage, P., El Nashar, A. & Brudi, P. The DYSlipidemia International Study (DYSIS)-Egypt: A report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment. Egypt. Hear. J. 65, 223\u2013232 (2013).","journal-title":"Egypt. Hear. J."},{"key":"42341_CR29","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cjca.2020.11.001","volume":"37","author":"D Lau","year":"2021","unstructured":"Lau, D. & McAlister, F. A. Implications of the COVID-19 pandemic for cardiovascular disease and risk-factor management. Can. J. Cardiol. 37, 722\u2013732 (2021).","journal-title":"Can. J. Cardiol."},{"key":"42341_CR30","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.2147\/RMHP.S265264","volume":"13","author":"L Degli Esposti","year":"2020","unstructured":"Degli Esposti, L., Buda, S., Nappi, C., Paoli, D. & Perrone, V. Implications of COVID-19 infection on medication adherence with chronic therapies in Italy: A proposed observational investigation by the fail-to-refill project. Risk Manag. Healthc. Policy 13, 3179\u20133185 (2020).","journal-title":"Risk Manag. Healthc. Policy"},{"key":"42341_CR31","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.2147\/JMDH.S313626","volume":"14","author":"TA Hassan","year":"2021","unstructured":"Hassan, T. A. et al. New strategies to improve patient adherence to medications for noncommunicable diseases during and after the COVID-19 era identified via a literature review. J. Multidiscip. Healthc. 14, 2453\u20132465 (2021).","journal-title":"J. Multidiscip. Healthc."},{"key":"42341_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41569-021-00541-4","volume":"18","author":"A Pirillo","year":"2021","unstructured":"Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D. & Catapano, A. L. Global epidemiology of dyslipidaemias. Nat. Rev. Cardiol. 18, 689\u2013700 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"42341_CR33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.metabol.2008.11.002","volume":"58","author":"P Mirmiran","year":"2009","unstructured":"Mirmiran, P., Noori, N., Zavareh, M. B. & Azizi, F. Fruit and vegetable consumption and risk factors for cardiovascular disease. Metabolism 58, 460\u2013468 (2009).","journal-title":"Metabolism"},{"key":"42341_CR34","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1021\/jf0116698","volume":"50","author":"H Suido","year":"2002","unstructured":"Suido, H. et al. A mixed green vegetable and fruit beverage decreased the serum level of low-density lipoprotein cholesterol in hypercholesterolemic patients. J. Agric. Food Chem. 50, 3346\u20133350 (2002).","journal-title":"J. Agric. Food Chem."},{"key":"42341_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ajcn\/74.1.80","volume":"74","author":"E Obarzanek","year":"2001","unstructured":"Obarzanek, E. et al. Effects on blood lipids of a blood pressure-lowering diet: The Dietary Approaches to Stop Hypertension (DASH) Trial. Am. J. Clin. Nutr. 74, 80\u201389 (2001).","journal-title":"Am. J. Clin. Nutr."},{"key":"42341_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00400","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Predictors of the prevalence of dyslipidemia and influencing factors for young health examination cohort: A cross-sectional survey. Front. Public Health https:\/\/doi.org\/10.3389\/fpubh.2020.00400 (2020).","journal-title":"Front. Public Health"},{"key":"42341_CR37","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(18)33197-0","volume":"393","author":"G Danaei","year":"2019","unstructured":"Danaei, G. et al. Iran in transition. Lancet 393, 1984\u20132005 (2019).","journal-title":"Lancet"},{"key":"42341_CR38","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S0140-6736(18)31992-5","volume":"392","author":"NCD Countdown 2030 collaborators","year":"2018","unstructured":"NCD Countdown 2030 collaborators. NCD Countdown 2030: Worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 392, 1072\u20131088 (2018).","journal-title":"Lancet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42341-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42341-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42341-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T06:23:27Z","timestamp":1700288607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-42341-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["42341"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-42341-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2677772\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15499"}}